GlassScriptPhysician profile
Paul S Rabinowitz
NPI 1871564716
$57,067.03
in general payments reported to CMS, 2019-2025
38 companies · $4,162 in 2025
The $4,162 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $9,131 · 2021: $9,173 · 2022: $11K · 2023: $3,571 · 2024: $3,367 · 2025: $4,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,992.34 |
| Education | $107.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $26,819.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,315.22 | 2019-2025 | Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $4,264.22 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $4,127.44 | 2019-2023 | Xolair |
| Astrazeneca Pharmaceuticals LP | $3,134.63 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,266.17 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $1,512.53 | 2019-2022 | |
| Abbvie INC. | $1,084.75 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,021.68 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $989.10 | 2019-2025 | |
| Grifols USA, LLC | $824.65 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $800.72 | 2020-2025 | Cuvitru, Takhzyro |
| Csl Behring | $788.71 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Pfizer INC. | $736.96 | 2019-2025 | |
| Amgen INC. | $556.97 | 2021-2025 | Tezspire |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rabinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.